We are live on ! Find out more
KAPA

Kairos Pharma
KAPA

14 hedge funds and large institutions have $506K invested in Kairos Pharma in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

193% more capital invested

Capital invested by funds: $173K → $506K (+$333K)

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

40% more funds holding

Funds holding: 10 → 14 (+4)

0.85% more ownership

Funds ownership: 1.3% → 2.15% (+0.85%)

Holders
14
Holders Change
+4
Holders Change %
+40%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$151K
2
Two Sigma Investments
Two Sigma Investments
New York
+$52.3K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$50.3K
4
State Street
State Street
Massachusetts
+$27.5K
5
FIA
FNY Investment Advisers
New York
+$26.9K

Top Sellers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
-$57.5K
2
HF
HRT Financial
New York
-$9K
3
UBS Group
UBS Group
Switzerland
-$3.98K
4
Citigroup
Citigroup
New York
-$3.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$154K +$151K +131,828 New
Geode Capital Management
2
Geode Capital Management
Massachusetts
$77K +$50.3K +43,996 +202%
Two Sigma Investments
3
Two Sigma Investments
New York
$53.6K +$52.3K +45,789 New
ACA
4
Aptus Capital Advisors
Alabama
$51.8K – – –
SFG
5
SevenBridge Financial Group
Pennsylvania
$37.7K – – –
TSS
6
Two Sigma Securities
New York
$29.1K +$13K +11,340 +84%
State Street
7
State Street
Massachusetts
$28.2K +$27.5K +24,100 New
FIA
8
FNY Investment Advisers
New York
$27K +$26.9K +23,500 New
QC
9
Quadrature Capital
United Kingdom
$17.4K +$17K +14,887 New
XT
10
XTX Topco
Cayman Islands
$14.5K -$57.5K -50,338 -80%
UBS Group
11
UBS Group
Switzerland
$7K -$3.98K -3,479 -37%
TRCT
12
Tower Research Capital (TRC)
New York
$6.97K +$2.47K +2,160 +57%
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$1K +$1.14K +1,000 New
Bank of America
14
Bank of America
North Carolina
$356 +$289 +253 +496%
HF
15
HRT Financial
New York
– -$9K -13,239 Closed
Citigroup
16
Citigroup
New York
– -$3.9K -5,499 Closed

KAPA Hedge Fund Activity: Q3 2025 in Review

14 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Kairos Pharma (KAPA) for Q3 2025, worth a combined $506K — up 193% from $173K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new KAPA positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $151K. The largest seller was XTX Topco, cutting an estimated $57.5K.

  • 14 institutional investors held Kairos Pharma (KAPA) as of Q3 2025, up from 10 in Q2 2025.
  • Funds reported $506K of Kairos Pharma stock for Q3 2025, up 193% quarter-over-quarter.
  • 6 funds opened new Kairos Pharma positions in Q3 2025 and 2 closed out, a net change of +4 holders.
  • The largest Kairos Pharma buyer in Q3 2025 was Vanguard Group, an estimated $151K added.
  • The largest Kairos Pharma seller in Q3 2025 was XTX Topco, an estimated $57.5K sold.

Based on aggregated 13F filings for Q3 2025.